Healthcare

● The FDA has told Reviva Pharmaceuticals it wants additional efficacy and safety data on schizophrenia candidate brilaroxazine before an NDA filing, prompting a planned RECOVER-2 Phase 3 trial. The company has since raised $10 million, delisted from Nasdaq to the OTCQB, and reported …

● SeaStar Medical secured dedicated hospital billing codes for its pediatric kidney-injury device and posted 69% quarterly revenue growth, but the company remains pre-revenue in its larger adult market and is burning cash faster than sales are arriving.

● Senti Biosciences plans to hand its clinical-stage gene-circuit pipeline, including lead cell therapy SENTI-202, to a newly formed private company controlled by its largest investor, replacing direct ownership with contingent value rights worth up to $60 million tied to future milestones.

● Phio Pharmaceuticals expanded its INTASYL patent estate to 54 issued patents in July 2026, days after manufacturing partner Nitto Denko Avecia began commercial-scale production of lead candidate PH-762. The micro-cap remains pre-revenue, with roughly $17 million in cash and heavy share dilution.

● On July 9, 2026, the FDA cleared Quoin Pharmaceuticals to begin a Phase 2 study of QRX003 in Peeling Skin Syndrome, a second indication for its lead topical candidate, arriving alongside a string of regulatory and patent milestones but a thin cash position.

Oneview Healthcare Plc (ASX:ONE) topped the All Ordinaries on 30 July 2026, closing at 17 cents on a falling market. But with no signed Epic Bedside Hub contract yet, how much of the move is real?

Artrya Limited (ASX:AYA) tumbled 14.47% to $4.08 on 30 July 2026, a day after a quarterly operational update, as investors weighed a still-pending US regulatory decision against the AI heart-imaging company's ongoing cash burn.